<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In order to study whether <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">erythroleukemia</z:e> was really a subtype of <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, the clinical laboratory characteristics and development of disease in 21 cases of <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">erythroleukemia</z:e> were analyzed </plain></SENT>
<SENT sid="1" pm="."><plain>The results indicated that the percentage of patients with leucocytopenia, <z:hpo ids='HP_0001903'>anemia</z:hpo> and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> were 42.9%, 81% and 81% respectively at the time of diagnosis </plain></SENT>
<SENT sid="2" pm="."><plain>These were 85.7% of patients with myelocytes and premonocyte, 52.4% of patients with erythroblast in their blood smear respectively </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of the bone marrow showed active or significantly active proliferation </plain></SENT>
<SENT sid="4" pm="."><plain>The median percentage of erythro-lineage, myeloblast of NEC and displasia were (58.3 +/- 8.0)%, (58.0 +/- 18.4)% and 66.7% respectively, that is different from typical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>52.4% of M(6) patients transferred to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M(2) subtype in the disease progression </plain></SENT>
<SENT sid="6" pm="."><plain>11/19 cases (57.4%) achieved remission (CR 10; PR 1) after chemotherapy </plain></SENT>
<SENT sid="7" pm="."><plain>The median remission length were 6 months for CR patients and 2 months for PR patients, but most of CR patients displayed obvious displasia of bone marrow and cytopenia of blood in the period of CR </plain></SENT>
<SENT sid="8" pm="."><plain>The median survival length of M(6) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>--&gt;M(6) from time of diagnosis were 13.0 +/- 13.2 and 2.3 +/- 1.3 months respectively </plain></SENT>
<SENT sid="9" pm="."><plain>It is concluded that there are differences between M(6) and typical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Most of M(6) patients would rather be classified <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t with over-<z:mpath ids='MPATH_134'>hyperplasia</z:mpath> of erythron lineage than a subtype of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>